CLAIMS

1. A pharmaceutical granulated product having improved granulatability, which contains a pharmaceutical compound with poor wettability and a surfactant.

2. A granulated product, wherein the product contains a compound with poor wettability and a surfactant, and at least about 35% by weight with respect to the total weight of the product does not pass through a 100-mesh sieve.

3. The granulated product according to claim 2, wherein the weight ratio of the compound and the surfactant is 1 : about 0.001 to about 2.

4. The granulated product according to claim 3, wherein the weight ratio is 1 : about 0.001 to less than 1.

5. The granulated product according to claim 3, wherein the weight ratio is 1 : about 0.001 to less than 0.1.

6. The granulated product according to claim 3, wherein the weight ratio is 1 : about 0.005 to about 0.05.

7. The granulated product according to claim 2, wherein the ratio of the compound with respect to the total granulated product is about 20% by weight or more.

8. The granulated product according to claim 2, wherein the compound is a pharmaceutical compound.

9. A molded product made by molding the granulated product according to any one of claims 2 to 8.

10. A method for improving granulatability of a pharmaceutical composition containing a pharmaceutical compound with poor

wettability, which comprises adding a surfactant before or during the granulation.

11. A method for preparing a granulated product containing a compound with poor wettability, having improved granulatability, which comprises adding a surfactant in the weight ratio of about 0.001 to about 2 with respect to the compound before or during the granulation.

12. The method according to claim 11, wherein a granulated product is obtained in which at least about 35% by weight with respect to the total weight of the product does not pass through a 100-mesh sieve.

13. The method according to claim 11, which involves wet granulation in a binder solution containing a surfactant.

14. The method according to claim 13, wherein the concentration of the surfactant in the binder solution is about 1 to about 1,000 mmol/L.

15. The method according to claim 13, wherein the concentration of the surfactant in the binder solution is about 10 to about 100 mmol/L.

16. The method according to claim 11, wherein the compound is a pharmaceutical compound.

17. A method for preparing a molded product, comprising molding the granulated product which is obtained by the method according to any one of claims 11 to 16.

18. A use of a surfactant for improving granulatability during the granulation of a pharmaceutical composition.

19. An agent for improving granulatability during the granulation of a pharmaceutical composition, which contains a surfactant.